Nanorobots are autonomous, programmable nano-scale devices designed to navigate the intricate terrain of the human body to detect and treat diseases like cancer.

Our Duobots™ technology is designed to early diagnose and treat pancreatic cancer – specifically pancreatic ductal adenocarcinoma – PDAC – the most common and aggressive form of pancreatic cancer, with the most devastating human impact.

​

Duobots™ are designed with a navigational system that seeks out pancreatic cancer in the body. Once located, and powered by AI-driven software, it’s designed to wirelessly collate diagnostic data of the disease forming at its earliest stage – at a cellular level. It’s also designed to undertake tissue analysis without the need for a biopsy.

​

When treatment is required, Duobots™ will be loaded with the relevant anti-cancer agent, this may be an existing anticancer drug or a new drug on the market, and delivered in high concentrations to cancer cells, increasing efficacy and minimising side effects. What sets our technology apart is its real-time monitoring potential, which will lay the groundwork for treatment plans to be agilely reviewed and adjusted based on real-time insights, rather than at intermittent cycles.

​

Ultimately, these combined capabilities are designed to help pancreatic cancer be detected early, and where cancer is detected, to help patients achieve remission sooner.